menu
    • menu

    Company profile for Rallybio

    NEW Drugs in Dev: 6
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Rallybio is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. We are focused on rapidly advancing our pipeline of promising product candidates and on further expanding our portfolio to execute on our mission. The Company’s lead product candidate, RLYB211, is in development for the prevention of fetal and neon...
    Rallybio is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. We are focused on rapidly advancing our pipeline of promising product candidates and on further expanding our portfolio to execute on our mission. The Company’s lead product candidate, RLYB211, is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    RallybioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    234 Church Street Suite 1020 New Haven, CT 06510
    Telephone
    Telephone
    (203) 859-3820
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://rallybio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/rallybio/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rallybio, Candid Therapeutics Announce Merger
    Rallybio, Candid Therapeutics Announce Merger

    02 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-02/rallybio-corporation-and-candid-therapeutics-announce-merger-agreement

    PHARMIWEB
    02 Mar 2026
    Share Share
    Rallybio's RLYB116 Inhibits Terminal Complement in Ph1
    Rallybio's RLYB116 Inhibits Terminal Complement in Ph1

    17 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260216537287/en/Rallybio-Announces-Positive-Data-for-RLYB116-Phase-1-Study-Demonstrating-Complete-and-Sustained-Inhibition-of-Terminal-Complement

    BUSINESSWIRE
    17 Feb 2026
    Share Share
    Rallybio Announces Reverse Stock Split Of Common Stock
    Rallybio Announces Reverse Stock Split Of Common Stock

    03 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260203651741/en/Rallybio-Announces-Reverse-Stock-Split-of-Common-Stock

    BUSINESSWIRE
    03 Feb 2026
    Share Share
    Rallybio Unveils Q3 2025 Financials & Business Updates
    Rallybio Unveils Q3 2025 Financials & Business Updates

    06 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251105235045/en/Rallybio-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Updates

    BUSINESSWIRE
    06 Nov 2025
    Share Share
    Rallybio Completes 1st Cohort Dosing In RLYB116 Ph 1 PK/PD Study
    Rallybio Completes 1st Cohort Dosing In RLYB116 Ph 1 PK/PD Study

    25 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250924016253/en/Rallybio-Completes-Dosing-of-First-Cohort-in-RLYB116-Phase-1-Confirmatory-PharmacokineticPharmacodynamic-Study

    BUSINESSWIRE
    25 Sep 2025
    Share Share
    Rallybio Gets $12.5M Equity Milestone from Recursion for REV102
    Rallybio Gets $12.5M Equity Milestone from Recursion for REV102

    03 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-03/rallybio-receives-125-million-equity-milestone-payment-from-recursion-for-advancement-of-rev102-pr

    PHARMAWEB
    03 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search